No-one can launch biosimilars until patent expires next year
Breast cancer blockbuster facing potential trio of US competitors.
FDA panel backs Herceptin and Avastin biosimilars.
Investors concerned over strong placebo effect
Erenumab could be first new treatment in a decade.
Companies awaiting CV outcomes trial, and court decision in patent case